Luo Cong
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Machine Learning for Recurrence Risk of Pancreatic Cancer After Radical Resection (NCT05589480) | Luo Cong | 2022-08-01 |
| The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (NCT06378580) | Luo Cong | 2022-07-01 |
Track Luo Cong automatically
Every clearance here is in the API, with alerts when new ones post.